Aurinia Pharmaceuticals AUPH EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's EPS (diluted)?
- Aurinia Pharmaceuticals (AUPH) reported EPS (diluted) of $0.25 in Q1 2026.
- How has Aurinia Pharmaceuticals's EPS (diluted) changed year-over-year?
- Aurinia Pharmaceuticals's EPS (diluted) increased by 56.3% year-over-year, from $0.16 to $0.25.
- What is the long-term trend for Aurinia Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's EPS (diluted) has grown at a 10.2% compound annual growth rate (CAGR), from -$1.41 to $2.08.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.